Immunoreaction after radiofrequency and cryo ablation

Immunoreaction after radiofrequency and cryo ablation - Immunoreaction after RF and cryo ablation

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000012159

Enrollment

100

Registered

2013-10-30

Start date

2013-11-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients with malignant neoplasms that are treated by RFor cryo ablation

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Malignant neoplasms 2. Tumor that is treated by RFA or cryoablation 3. 20 years or more. 4. ECOG PS is 0 or 1. 5. Main organs are preserved 1) WBC of 2,500/mm3 or more, 2) Platelet count of 60,000/uL or more, 3) Hb of 10.0g/dL or more, 4) Serum bilirubin of 2.0 mg/dLor less, 5) ASTand ALT of 5 times of the institutionalupper limit or less, 6) Prothrombin time of 50% or less. 6. At least 4 weeks or more from the previous treatment. 7. Informed consent from the patient.

Exclusion criteria

Exclusion criteria: 1) Severe cormorbid disease. 2) Difficulty of oral intake. 3) A physician-in-charge judge as inadequate.

Design outcomes

Primary

Measure	Time frame
1. Analysis of cytokine 2. Cell-mediated immunity related to tumor antigen 3. Extraction of tumor RNA and DNA 4. Analysis of tumor antigen expression 5. Tumor gene analysis 6. Relashionship between prognosis and analysis results	—

Countries

Japan

Contacts

Public ContactKoichiro Yamakado

Mie University Hospital Department of Interevntional Radiology

yama@clin.meic.mie-u.ac.jp059-231-5029

Outcome results